About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The goal of the Shock, Organic Dysfunction and Resuscitation Research Group (SODIR) is comprehensive, innovative research into the areas of shock, acute respiratory failure, acute kidney failure, organic dysfunction, resuscitation and critical patient monitoring. In addition, the research group has a special interest in applying artificial intelligence as an instrument to find innovative solutions for critical patients.
SODIR has created the Clinical Research Unit for to participate in the clinical trials promoted by the industry. This Unit centralizes all the clinical trials that are developed in the Group and allows a professional management of clinical trials, being a very positive and highly valued imput by the pharma companys. The Unit also give support to competitive research projects. Actually we are working in 14 clinical trials focused mainly on the field of sepsis and infectious diseases. The Unit is formed by nursing and doctors exclusively dedicated to clinical research (24 hours, 7 days/week).
IP: Ricard Ferrer Roca
The line of research in acute respiratory failure has special interest in the study of the involvement of the interleukin 33 and its ST2 receptor in acute lung injury and its role as a possible therapeutic target. A model of acute lung injury in mice has been designed to show the prognostic efficacy of interleukin 33 and ST-2 plasma levels. Currently, SODIR is evaluating the possibility that treatment with anti-IL-33 antibodies may decrease the degree of inflammation in a murine experimental model of acute lung injury.
Another issue of special interest is the use of high flow nasal cannula supportive therapy. In this sense, SODIR has participated in a multicentric study, recently published in JAMA, analyzing the effect of high flow nasal cannula on postextubation respiratory failure.
Finally, SODIR is also involved in several multicentric international trials about the use of esophageal pressure to guide mechanical ventilation settings in patients with acute respiratory distress syndrome.
IP: Andres Francisco Pacheco Reyes
In close collaboration with the Oncology research group and the Hematology research group, the research line of Critical Oncohematology, has as a main objective the study of the complications associated to experimental treatments of the oncohematogy patients
IP: Candido Diaz Lagares
The study will be conducted in the Intensive Care Medicine Service of the Vall d’Hebron University Hospital and will validate the prognostic value of the NLRP3 biomarker.
SOFA-2 is being updated after thirty years to incorporate advances in diagnosis, monitoring and life support.
On European Antibiotic Awareness Day, we highlight the importance of using these medications responsibly and finding innovative solutions to combat this issue.
